{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:27:10Z","timestamp":1788848830680,"version":"build-2803163510"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Olatec","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Interleukin-1\u03b2 (IL-1\u03b2), a product of the NLRP3 inflammasome, modulates cardiac contractility and diastolic function. We proposed that OLT1177\u00ae (dapansutrile), a novel NLRP3 inhibitor, could preserve contractile reserve and diastolic function after myocardial infarction (MI). We used an experimental murine model of severe ischemic cardiomyopathy through the ligation of the left coronary artery without reperfusion, and after 7 days randomly assigned mice showing large anterior MI (&gt;4 akinetic segments), increased left ventricular (LV) dimensions ([LVEDD] &gt; 4.4 mm), and reduced function (LV ejection fraction &lt; 40%) to a diet that was enriched with OLT1177\u00ae admixed with the chow in the diet at 3.75 g\/kg (Group 1 [n = 10]) or 7.5 g\/kg (Group 2 [n = 9]), or a standard diet as the no-treatment control group (Group 3 [n = 10]) for 9 weeks. We measured the cardiac function and contractile reserve with an isoproterenol challenge, and the diastolic function with cardiac catheterization at 10 weeks following the MI surgery. When compared with the control (Group 3), the mice treated with OLT1177 (Group 1 and 2) showed significantly greater preservation of their contractile reserve (the percent increase in the left ventricular ejection fraction [LVEF] after the isoproterenol challenge was +33 \u00b1 11% and +40 \u00b1 6% vs. +9 \u00b1 7% in the standard diet; p &lt; 0.05 and p &lt; 0.005 for Group 1 and 2, respectively) and of diastolic function measured as the lower left ventricular end-diastolic pressure (3.2 \u00b1 0.5 mmHg or 4.5 \u00b1 0.5 mmHg vs. 10.0 \u00b1 1.6 mmHg; p &lt; 0.005 and p &lt; 0.009 respectively). No differences were noted between the resting LVEF of the MI groups. These effects were independent of the effects on the ventricular remodeling after MI. NLRP3 inflammasome inhibition with OLT1177\u00ae can preserve \u03b2-adrenergic responsiveness and prevent left ventricular diastolic dysfunction in a large non-reperfused anterior MI mouse model. OLT1177\u00ae could therefore be used to prevent the development of heart failure in patients with ischemic cardiomyopathy.<\/jats:p>","DOI":"10.3390\/molecules26123534","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:16:04Z","timestamp":1623248164000},"page":"3534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177\u00ae (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperfused Anterior Wall Myocardial Infarction"],"prefix":"10.3390","volume":"26","author":[{"given":"Joseph","family":"Aliaga","sequence":"first","affiliation":[{"name":"VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-5535","authenticated-orcid":false,"given":"Aldo","family":"Bonaventura","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Mezzaroma","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Outcome Studies, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Dhakal","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5786-5844","authenticated-orcid":false,"given":"Adolfo Gabriele","family":"Mauro","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Toldo","sequence":"additional","affiliation":[{"name":"VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","article-title":"The NLRP3 inflammasome in acute myocardial infarction","volume":"15","author":"Toldo","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1248\/bpb.b18-00369","article-title":"Role of NLRP3 Inflammasome in Cardiac Inflammation and Remodeling after Myocardial Infarction","volume":"42","author":"Takahashi","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1089\/ars.2014.5989","article-title":"The inflammasome in myocardial injury and cardiac remodeling","volume":"22","author":"Toldo","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Abbate, A., Salloum, F.N., Van Tassell, B.W., Vecile, E., Toldo, S., Seropian, I., Mezzaroma, E., and Dobrina, A. (2011). Alterations in the interleukin-1\/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027923"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","article-title":"Interleukin-1\u03b2 induces a reversible cardiomyopathy in the mouse","volume":"62","author":"Seropian","year":"2013","journal-title":"Inflamm. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting interleukin-1 in heart disease","volume":"128","author":"Toldo","year":"2013","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000106","article-title":"Interleukin-1\u03b2 blockade improves left ventricular systolic\/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse","volume":"64","author":"Toldo","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction","volume":"117","author":"Abbate","year":"2008","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jacbts.2017.06.005","article-title":"The IL-1\u03b2 Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats with Heart Failure","volume":"2","author":"Harouki","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1113\/expphysiol.2012.069831","article-title":"Interleukin-1\u03b2 blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse","volume":"98","author":"Toldo","year":"2013","journal-title":"Exp. Physiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction (from the Virginia Commonwealth University-Anakinra Remodeling Trial [2] [VCU-ART2] pilot study)","volume":"111","author":"Abbate","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e014941","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients with ST-Segment-Elevation Myocardial Infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e004373","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)","volume":"10","author":"Canada","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"ref_16","unstructured":"Virginia Commonwealth University (2021, March 17). Interleukin-1 Blockade in Recently Decompensated Heart Failure\u20142 (REDHART2), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03797001."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","article-title":"Usefulness of Canakinumab to Improve Exercise Capacity in Patients with Long-Term Systolic Heart Failure and Elevated C-Reactive Protein","volume":"122","author":"Trankle","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_19","unstructured":"OLATEC Lead Compound (2020, March 02). OLATEC. Available online: http:\/\/www.olatec.com\/lead-compound.html."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13075-018-1664-2","article-title":"NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis","volume":"20","author":"Marchetti","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","unstructured":"(2021, June 09). Phase 1 Safety and PK Study of OLT1177 Capsules, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02134964?term=olt1177&rank=2."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: An open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Jansen","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"A Phase IB, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with NYHA II-III Systolic Heart Failure","volume":"77","author":"Wohlford","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19725","DOI":"10.1073\/pnas.1108586108","article-title":"The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse","volume":"108","author":"Mezzaroma","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000247","article-title":"Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse","volume":"66","author":"Marchetti","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FJC.0000000000000658","article-title":"The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse","volume":"73","author":"Toldo","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/cvr\/cvz161","article-title":"Small animal models of heart failure","volume":"115","author":"Riehle","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-014-6559-0","article-title":"Tadalafil prevents acute heart failure with reduced ejection fraction in mice","volume":"28","author":"Salloum","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1073\/pnas.0611496104","article-title":"Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling","volume":"104","author":"Duncan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.hjc.2016.11.027","article-title":"Myocardial inotropic reserve: An old twist that constitutes a reliable index in the modern era of heart failure","volume":"57","author":"Parthenakis","year":"2016","journal-title":"Hellenic. J. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJM198207223070401","article-title":"Decreased catecholamine sensitivity and \u03b2-adrenergic-receptor density in failing human hearts","volume":"307","author":"Bristow","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Van Tassell, B.W., Arena, R.A., Toldo, S., Mezzaroma, E., Azam, T., Seropian, I.M., Shah, K., Canada, J., Voelkel, N.F., and Dinarello, C.A. (2012). Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033438"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2000915118","DOI":"10.1073\/pnas.2000915118","article-title":"Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion","volume":"118","author":"Tengesdal","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/FJC.0b013e3181f9a905","article-title":"Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3K\u03b3) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice","volume":"56","author":"Seropian","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacbts.2020.09.013","article-title":"Absence of NLRP3 Inflammasome in Hematopoietic Cells Reduces Adverse Remodeling After Experimental Myocardial Infarction","volume":"5","author":"Louwe","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_39","first-page":"1738","article-title":"Transthoracic echocardiography in mice","volume":"39","author":"Respress","year":"2010","journal-title":"J. Vis. Exp."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_41","unstructured":"Szymanski, M.W., and Singh, D.P. (2021). Isoproterenol, StatPearls Publishing."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCRESAHA.110.223925","article-title":"A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse","volume":"107","author":"Gao","year":"2010","journal-title":"Circ. Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/12\/3534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:12:40Z","timestamp":1760163160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/12\/3534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["molecules26123534"],"URL":"https:\/\/doi.org\/10.3390\/molecules26123534","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]}}}